<DOC>
	<DOCNO>NCT00990678</DOCNO>
	<brief_summary>The investigator want investigate HIV sero-positive male benefit vitamin D supplementation . The study run 16 week participant treat one three placebo control regime ( tablet ) : 1 . Calcium 2 . Calcium 25-hydroxy-vitamin D 3 . Calcium 25-hydroxy-vitamin D 1,25-dihydroxyvitamin D The endpoint : - Serum vitamin D - Parathyroid hormone - ionized calcium - T-lymphocyte fraction ( na√Øve , mature , Tregs ) - Osteocalcin ( bone metabolism )</brief_summary>
	<brief_title>Study Vitamin D Supplementation Male HIV Sero-positive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<criteria>male HIVpositive least 18 year old receive HiglyActiveAntiRetroviral Therapy ( HAART ) hypercalcemia tuberculosis osteoporosis bone disease cancer bone metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>human</keyword>
	<keyword>vitamin D</keyword>
	<keyword>1-hydroxy-vitamin D</keyword>
	<keyword>Rocaltrol</keyword>
	<keyword>calcium</keyword>
	<keyword>complementary therapy</keyword>
</DOC>